Drug
Somapacitan clinical trials
Also written NNC0195-0092.
- studies test it
- 15
- open now
- 0
- in phase 3
- 7
- first study started
- 2012
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
15 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 1
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Studies
Open first, then newest update. How each study uses somapacitan is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)CompletedPhase 3Novo Nordisk A/SNCT03811535Written as Somapacitan
- A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a DayActive, not recruitingPhase 2Novo Nordisk A/SNCT03878446Written as Somapacitan
- A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9Active, not recruitingPhase 3Novo Nordisk A/SNCT05723835Written as Somapacitan
- A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to GrowActive, not recruitingPhase 3Novo Nordisk A/SNCT05330325Written as Somapacitan
- A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.CompletedPhase 3Novo Nordisk A/SNCT04970654Written as somapacitan
- A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone DeficiencyCompletedPhase 1Novo Nordisk A/SNCT01973244Written as somapacitan
- First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy SubjectsCompletedPhase 1Novo Nordisk A/SNCT01514500Written as somapacitan
- A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone DeficiencyCompletedPhase 1Novo Nordisk A/SNCT01706783Written as somapacitan
- A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone DeficiencyCompletedPhase 3Novo Nordisk A/SNCT03075644Written as somapacitan
- Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.CompletedPhase 3Novo Nordisk A/SNCT02229851Written as somapacitan
- A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone DeficiencyCompletedPhase 3Novo Nordisk A/SNCT02382939Written as somapacitan
- Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal FunctionCompletedPhase 1Novo Nordisk A/SNCT03186495Written as Somapacitan
- A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy SubjectsCompletedPhase 1Novo Nordisk A/SNCT03905850Written as somapacitan
- Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.CompletedPhase 1Novo Nordisk A/SNCT03212131Written as Somapacitan
- A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male SubjectsCompletedPhase 1Novo Nordisk A/SNCT02962440Written as somapacitan
Given in every arm · 1 — somapacitan is usual care beside what is tested
Codes
What other systems call somapacitan · ClinicalTrials.gg INT001671
- MeSH (NLM) C000718308somapacitanOne source ClinicalTrials.gov
- UNII (FDA) 8FOJ430U94SOMAPACITANConfirmed FDA, Wikidata
- RxNorm 2557373One source FDA
- Wikidata Q27270325somapacitanConfirmed FDA, Wikidata
- NCI Thesaurus C152394SomapacitanOne source FDA
- DrugBank DB15093One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718308 | somapacitan | One source ClinicalTrials.gov |
| UNII (FDA) | 8FOJ430U94 | SOMAPACITAN | Confirmed FDA, Wikidata |
| RxNorm | 2557373 | — | One source FDA |
| Wikidata | Q27270325 | somapacitan | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152394 | Somapacitan | One source FDA |
| DrugBank | DB15093 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.